A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT ID: NCT01525550
Last Updated: 2019-07-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
106 participants
INTERVENTIONAL
2012-06-06
2018-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
NCT02282059
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01121562
Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
NCT02713763
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
NCT02315625
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
NCT01215578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sunitinib
sunitinib
Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sunitinib
Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progression within 12 months prior to study enrollment.
* Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
Exclusion Criteria
* Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univeristy of California
Orange, California, United States
Columbia University Medical Center
New York, New York, United States
Barwon Health - University Hospital Geelong
Geelong, Victoria, Australia
Cliniques Universitaires Saint-Luc, Gastroenterologie
Brussels, Brussels Gewest, Belgium
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
307 Hospital of PLA
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Nanjing Bayi Hospital
Nanjing, Jiangsu, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Fudan University Shanghai Cancer Center
Shanghai, , China
Zhongshan Hospital Fudan University
Shanghai, , China
Masarykuv onkologicky ustav
Brno, , Czechia
Fakultni poliklinika
Prague, , Czechia
Vseobecna Fakultni Nemocnice v Praze
Prague, , Czechia
Hôpital Beaujon
Clichy, , France
Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika
Budapest, , Hungary
Tata Memorial Hospital
Mumbai, Maharashtra, India
IEO Istituto Europeo di Oncologia, IRCCS
Milan, , Italy
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, , Norway
Centrul de Oncologie Sf. Nectarie
Craiova, Dolj, Romania
Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
Bucharest, , Romania
Narodny Onkologicky ustav
Bratislava, , Slovakia
Wits Clinical Research
Johannesburg, Gauteng, South Africa
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fazio N, Kulke M, Rosbrook B, Fernandez K, Raymond E. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Target Oncol. 2021 Jan;16(1):27-35. doi: 10.1007/s11523-020-00784-0. Epub 2021 Jan 7.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-004363-74
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A6181202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.